Screener
Rapport Therapeutics, Inc. RAPP Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the six monthsended June 30, 2026 | For the six monthsended June 30, 2025 |
|---|---|---|
| Non-cash loss on sale of property and equipment | 152 | - |
| Net (accretion) and amortization of investments in marketable securities | (19) | (528) |
| Non-cash lease expense | 1,177 | 894 |
| Stock-based compensation expense | 14,165 | 8,429 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (293) | - |
| Prepaid expenses and other current assets | (2,344) | (5,144) |
| Other assets | 346 | (548) |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s stock-based comp?
- Rapport Therapeutics, Inc. (RAPP) reported stock-based comp of $7.2M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Rapport Therapeutics, Inc.'s stock-based comp increased by 64.1% year-over-year, from $4.39M to $7.2M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Rapport Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude